Market Overview

UPDATE: Morgan Stanley Reiterates on Synageva BioPharma as Brain-Blood Barrier Study is Good Next Step

Share:
Related GEVA
Ultragenyx Downgraded At Morgan Stanley, Valuation 'Stretched' And Pipeline Faces Execution Risk
JMP Starts Ultragenyx At Outperform, Pipeline Maturity Expected To Continue

In a report published Tuesday, Morgan Stanley analyst David Friedman reiterated an Overweight rating on Synageva BioPharma (NASDAQ: GEVA), but removed the $118.00 price target.

In the report, Morgan Stanley “Synageva recently started an MPS3b pt study (n=6) where they will be assessing the degree of blood-brain barrier (BBB) leakage. Based on their pre-clin animal work, the route of dosing for SBC-103, their drug for MPS3b, is still undetermined between IV or intrathecal (IT). A key first step for the company and the Street is to identify whether the BBB of MPS3b pts is ‘leaky enough' to accommodate efficient IV dosing.”

Synageva BioPharma closed on Monday at $82.97.

Latest Ratings for GEVA

DateFirmActionFromTo
May 2015BairdDowngradesOutperformNeutral
Mar 2015JP MorganDowngradesOverweightNeutral
Feb 2015CitigroupMaintainsNeutral

View More Analyst Ratings for GEVA
View the Latest Analyst Ratings

Posted-In: David Friedman Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (GEVA)

Get Benzinga's Newsletters